Patent intelligence · US
US 10786461
Onapristone extended-release compositions and methods
Onapristone extended-release compositions and methods
Patent details — US 10786461
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 29, 2020
- Expiration
- Sep 24, 2040
- Applicant
- CONTEXT BIOPHARMA, INC.
- Claims
- 16
- CPC classes
- A61K, A61K31/575, A61K9/20, A61K9/2054
Quick answer
US 10786461 (Onapristone extended-release compositions and methods) is held by CONTEXT BIOPHARMA, INC.. Status: granted. Granted Sep 29, 2020. Expires Sep 24, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CONTEXT BIOPHARMA, INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/575, A61K9/20, A61K9/2054, A61P, A61P35/00
More from CONTEXT BIOPHARMA, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10786461?
US 10786461 (Onapristone extended-release compositions and methods) is held by CONTEXT BIOPHARMA, INC.. Status: granted. Granted Sep 29, 2020. Expires Sep 24, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10786461?
CONTEXT BIOPHARMA, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 10786461 expire?
Our index shows an expiration date of Sep 24, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.